Form 8-K - Current report:
SEC Accession No. 0001193125-25-004133
Filing Date
2025-01-10
Accepted
2025-01-10 08:13:47
Documents
15
Period of Report
2025-01-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d796195d8k.htm   iXBRL 8-K 28285
2 EX-99.1 d796195dex991.htm EX-99.1 10499
6 GRAPHIC g796195dsp5.jpg GRAPHIC 4378
  Complete submission text file 0001193125-25-004133.txt   176116

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA annx-20250110.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE annx-20250110_lab.xml EX-101.LAB 18757
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE annx-20250110_pre.xml EX-101.PRE 11708
17 EXTRACTED XBRL INSTANCE DOCUMENT d796195d8k_htm.xml XML 3768
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 25520539
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)